Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 285125, 7 pages
http://dx.doi.org/10.1155/2015/285125
Research Article

Reduced Histone H3 Acetylation in CD4+ T Lymphocytes: Potential Mechanism of Latent Autoimmune Diabetes in Adults

1Department of Endocrinology, Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, Zhejiang 322000, China
2Department of Surgery, Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, Zhejiang 322000, China

Received 27 September 2015; Revised 7 December 2015; Accepted 10 December 2015

Academic Editor: Marco E. M. Peluso

Copyright © 2015 Xi-yu Liu and Jiang-feng Xu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Z. Zhou, Y. Xiang, L. Ji et al., “Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study,” Diabetes, vol. 62, no. 2, pp. 543–550, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Marek-Trzonkowska, M. Myśliwiec, A. Dobyszuk et al., “Therapy of type 1 diabetes with CD4+CD25highCD127-regulatory T cells prolongs survival of pancreatic islets—results of one year follow-up,” Clinical Immunology, vol. 153, no. 1, pp. 23–30, 2014. View at Publisher · View at Google Scholar
  3. R. Dahan, J. A. Gebe, A. Preisinger et al., “Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive T cell epitope,” Journal of Autoimmunity, vol. 47, pp. 83–93, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Laugesen, J. A. Østergaard, and R. D. Leslie, “Latent autoimmune diabetes of the adult: current knowledge and uncertainty,” Diabetic Medicine, vol. 32, no. 7, pp. 843–852, 2015. View at Publisher · View at Google Scholar
  5. K. J. Basile, V. C. Guy, S. Schwartz, and S. F. A. Grant, “Overlap of genetic susceptibility to type 1 diabetes, type 2 diabetes, and latent autoimmune diabetes in adults,” Current Diabetes Reports, vol. 14, no. 11, article 550, 2014. View at Publisher · View at Google Scholar
  6. A. Galvani and C. Thiriet, “Nucleosome dancing at the tempo of histone tail acetylation,” Genes, vol. 6, no. 3, pp. 607–621, 2015. View at Publisher · View at Google Scholar
  7. D. Molina-Serrano and A. Kirmizis, “Beyond the histone tail: acetylation at the nucleosome dyad commands transcription,” Nucleus, vol. 4, no. 5, pp. 343–348, 2013. View at Google Scholar · View at Scopus
  8. B. Gupta and R. D. Hawkins, “Epigenomics of autoimmune diseases,” Immunology and Cell Biology, vol. 93, no. 3, pp. 271–276, 2015. View at Publisher · View at Google Scholar
  9. L. Haery, R. C. Thompson, and T. D. Gilmore, “Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy,” Genes Cancer, vol. 6, no. 5-6, pp. 184–213, 2015. View at Google Scholar
  10. P. Tu, X. Li, B. Ma et al., “Liver histone H3 methylation and acetylation may associate with type 2 diabetes development,” Journal of Physiology and Biochemistry, vol. 71, no. 1, pp. 89–98, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Wang, Y. Wang, M. Luo et al., “Novel curcumin analog C66 prevents diabetic nephropathy via JNK pathway with the involvement of p300/CBP-mediated histone acetylation,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1852, no. 1, pp. 34–46, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. Reddy, E. Zhang, and R. Natarajan, “Epigenetic mechanisms in diabetic complications and metabolic memory,” Diabetologia, vol. 58, no. 3, pp. 443–455, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Miao, Z. Chen, L. Zhang et al., “Profiles of epigenetic histone post-translational modifications at type 1 diabetes susceptible genes,” Journal of Biological Chemistry, vol. 287, no. 20, pp. 16335–16345, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Miao, Z. Chen, S. Genuth et al., “Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes,” Diabetes, vol. 63, no. 5, pp. 1748–1762, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Hernandez, A. Mollo, J. R. Marsal et al., “Insulin secretion in patients with latent autoimmunediabetes (LADA): half way between type 1 and type 2diabetes: action LADA 9,” BMC Endocrine Disorders, vol. 15, article 1, 2015. View at Google Scholar
  16. T. Tuomi, N. Santoro, S. Caprio, M. Cai, J. Weng, and L. Groop, “The many faces of diabetes: a disease with increasing heterogeneity,” The Lancet, vol. 383, no. 9922, pp. 1084–1094, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Ü. Kaniskan, K. D. Konze, and J. Jin, “Selective inhibitors of protein methyltransferases,” Journal of Medicinal Chemistry, vol. 58, no. 4, pp. 1596–1629, 2015. View at Publisher · View at Google Scholar
  18. C. C. Thinnes, K. S. England, A. Kawamura, R. Chowdhury, C. J. Schofield, and R. J. Hopkinson, “Targeting histone lysine demethylases—progress, challenges, and the future,” Biochimica et Biophysica Acta—Gene Regulatory Mechanisms, vol. 1839, no. 12, pp. 1416–1432, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Genuth, “Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes,” Endocrine Practice, vol. 12, supplement 1, pp. 34–41, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. J. M. Lachin, N. H. White, D. P. Hainsworth, W. Sun, P. A. Cleary, and D. M. Nathan, “Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC,” Diabetes, vol. 64, no. 2, pp. 631–642, 2015. View at Google Scholar